Volume 53, Issue 5, Pages (May 1998)

Slides:

Advertisements

Similar presentations

Volume 72, Issue 7, Pages (October 2007)

Advertisements

Volume 64, Issue 6, Pages (December 2003)

Volume 55, Issue 6, Pages (June 1999)

Renal manifestations in Fabry disease and therapeutic options

Paraneoplastic glomerulopathies: New insights into an old entity

Volume 59, Issue 4, Pages (April 2001)

Volume 61, Issue 2, Pages (February 2002)

Volume 61, Issue 4, Pages (April 2002)

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis Y. Huang, W.A. Border, D.A. Lawrence, N.A.

Volume 67, Issue 5, Pages (May 2005)

Volume 68, Issue 2, Pages (August 2005)

Volume 68, Issue 5, Pages (November 2005)

Volume 56, Issue 1, Pages (July 1999)

Volume 75, Issue 10, Pages (May 2009)

Volume 62, Issue 6, Pages (December 2002)

Hua Liu, Steven A. Bigler, Jeffrey R. Henegar, Radhakrishna Baliga

Volume 63, Issue 1, Pages (January 2003)

Volume 55, Issue 4, Pages (April 1999)

Volume 56, Issue 3, Pages (September 1999)

Volume 64, Issue 4, Pages (October 2003)

Volume 58, Issue 5, Pages (November 2000)

VEGF receptor 2 blockade leads to renal cyst formation in mice

Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris

Volume 56, Issue 2, Pages (August 1999)

Volume 66, Issue 1, Pages (July 2004)

Volume 61, Issue 2, Pages (February 2002)

Mohammed S. Razzaque, Ph.D., Takashi Taguchi Kidney International

Isotretinoin alleviates renal damage in rat chronic glomerulonephritis

Volume 64, Issue 4, Pages (October 2003)

Volume 67, Issue 5, Pages (May 2005)

Volume 60, Issue 6, Pages (December 2001)

Volume 58, Issue 1, Pages (July 2000)

Volume 70, Issue 2, Pages (July 2006)

Volume 88, Issue 4, Pages (October 2015)

Regulatory interactions of αβ and γλ T cells in glomerulonephritis

Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis J. Mahmood, F. Khan, S. Okada,

Volume 61, Issue 6, Pages (June 2002)

Volume 56, Issue 3, Pages (September 1999)

Volume 61, Issue 6, Pages (June 2002)

Volume 66, Issue 5, Pages (November 2004)

Volume 71, Issue 7, Pages (April 2007)

Hypertension, race, and glomeruli: more than simply a numbers game

Volume 66, Issue 4, Pages (October 2004)

Volume 59, Issue 4, Pages (April 2001)

B. Li, T. Morioka, M. Uchiyama, T. Oite Kidney International

Volume 71, Issue 9, Pages (May 2007)

C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo

Volume 72, Issue 7, Pages (October 2007)

Volume 64, Issue 3, Pages (September 2003)

Volume 55, Issue 3, Pages (March 1999)

Volume 69, Issue 11, Pages (June 2006)

Lipid-binding proteins in rat and human kidney

Nitric oxide and glomerulonephritis

Volume 60, Issue 5, Pages (November 2001)

Volume 65, Issue 6, Pages (June 2004)

Volume 66, Issue 3, Pages (September 2004)

Volume 57, Issue 5, Pages (May 2000)

Volume 54, Pages S189-S191 (September 1998)

TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis C.Y. Song, B.C. Kim, H.K. Hong,

The treatment of acute interstitial nephritis: More data at last

Volume 58, Issue 1, Pages (July 2000)

Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats

Volume 63, Issue 1, Pages (January 2003)

Volume 58, Issue 3, Pages (September 2000)

Volume 73, Issue 5, Pages (March 2008)

T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis Masashi Haraguchi, Wayne A. Border, Yufeng Huang,

Volume 63, Issue 6, Pages (June 2003)

Unmasking a unique glomerular lesion

Volume 78, Issue 3, Pages (August 2010)

Presentation transcript:

Volume 53, Issue 5, Pages 1314-1320 (May 1998) Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat Masahiko Kushiro, Kenichi Shikata, Hikaru Sugimoto, Yasushi Shikata, Nobuyuki Miyatake, Jun Wada, Masayuki Miyasaka, Hirofumi Makino Kidney International Volume 53, Issue 5, Pages 1314-1320 (May 1998) DOI: 10.1046/j.1523-1755.1998.00881.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Effect of beraprost on urinary protein excretion of experimental crescentic glomerulonephritis. Beraprost-treated rats (▪) have significantly lower urinary protein excretion than saline-treated control rats (□) from 12 days after induction of glomerulonephritis. **P < 0.01, *P < 0.05. Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Light microscopic appearance of control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum. In the kidney of beraprost-treated rats, only 10% of glomeruli shows crescentic formation, although 80% of glomeruli shows crescentic formation in control rats (hematoxylin and eosin; ×200). Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Immunofluorescence micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum stained with antibody against rat fibrinogen. Fibrinogen is intensely stained in the capillary, mesangial areas and cellular crescent in the glomeruli of the control rats. In beraprost-treated rats, the staining intensities of rat fibrinogen are significantly lower than those in control rats (×200). Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 4 Immunofluorescence micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum stained with antibody against rat ICAM-1. The control group exhibits ICAM-1 expression intensely along the capillary wall. In the beraprost-treated rats, ICAM-1 is expressed faintly in segmental capillary wall (×200). Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 5 Immunoperoxidase micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum stained with antibody against rat monocytes/macrophages. The control group exhibits a massive influx of macrophages into the glomeruli. In contrast, in beraprost-treated group, infiltration of macrophages is significantly prevented (×400). Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 6 Glomerular staining scores of fibrinogen (A) and ICAM-1 (B), and the number of monocytes/macrophages (C) of experimental crescentic glomerulonephritis. Symbols are: (□) control group; (▪) beraprost-treated group;*P < 0.01, **P < 0.05. Kidney International 1998 53, 1314-1320DOI: (10.1046/j.1523-1755.1998.00881.x) Copyright © 1998 International Society of Nephrology Terms and Conditions